Ma K* and Zhang Y
Department of Pharmacology, Shenyang Pharmaceutical University, ChinaFulltext PDF
Along with the widely use of anti-angiogenic therapies, recognition of the anti-VEGF related renal injury has increased. However, renal biopsy is rarely available in cancer patients who underwent systemic treatment; therefore, the renal consequences caused by inhibition of VEGF are usually underestimated. In here, we report a case of pancreatic cancer patient who developed proteinuria under the treatment of bevacizumab. The efficacy and side effects of bevacizumab were reported, and the mechanism of proteinuria and the principle of treatment were explored.
Ma K, Zhang Y. Anti-Angiogenic Therapy-Related Proteinuria in a Patient with Advanced Pancreatic Cancer: A Case Report and Review of the Literature. Clin Case Rep Int. 2022; 6: 1364.